Research Briefs: Study Updates From Neuronetics, Edwards
This article was originally published in The Gray Sheet
Neuronetics starts study enrollment for its NeuroStar transcranial magnetic stimulation to treat postpartum depression. Edwards delays enrollment for Sapien XT Cohort A of the PARTNER II trial. More research news.
You may also be interested in...
Neuronetics Inc. forged a new specialty of sorts, the interventional psychiatrist. Unlike other interventional approaches, the externally applied NeuroStar delivers transcranial magnetic stimulation to the precise area of the brain responsible for intractable depression. The device is changing the lives of psychiatrists who launched “TMS” clinics, hoping to capture the early success, and potentially creating opportunities for medical devices designed to treat other brain-related disorders.
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.